Aprinoia Therapeutics is dedicated to establish a drug discovery and early development company that is based on innovation and scientific rigor and integrity.
Our goal is to create novel products to meet critical patient needs, including:
1) Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and
2) Novel therapies to improve the treatment of human neurological conditions.
Location: Taiwan, Taipei
Employees: 11-50
Total raised: $11M
Founded date: 2015
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 16.01.2018 | Series B | $11M | KTB Networ... | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 24.08.2023 | Wilbur Ross' SPAC backtracks on merger with Alzheimer's-focu... | Don’t count on the triumphant return of biotech special purpose acquisition company deals quite yet.... | fiercebiot... |
| 17.01.2018 | Taiwan’s Aprinoia Therapeutics raises $11m co-led by KTB Net... | Premium Taiwan-based Aprinoia Therapeutics Inc, a clinical-stage neuroscience biotech company, said... | dealstreet... |
| 16.01.2018 | Aprinoia Therapeutics Closes US$11M Series B Financing | Aprinoia Therapeutics Inc., a Taipei, Taiwan-based clinical-stage neuroscience biotech company, focu... | finsmes.co... |